Mass drug administration for scabies control in a population with endemic disease

New England Journal of Medicine

Volumn 373, Issue 24, 2015, Pages 2305-2313

  Romani, Lucia ^a   Whitfeld, Margot J ^b   Koroivueta, Josefa ^g   Kama, Mike ^g   Wand, Handan ^a   Tikoduadua, Lisi ^g   Tuicakau, Meciusela ^g   Koroi, Aminiasi ^g   Andrews, Ross ^c   Kaldor, John M ^a   Steer, Andrew C ^d,e,f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g Ministry of Health   (Fiji)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; PERMETHRIN; ANTIINFECTIVE AGENT; INSECTICIDE; SKIN CREAM;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; FEMALE; FIJI; FOLLOW UP; HUMAN; IMPETIGO; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MASS DRUG ADMINISTRATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCABIES; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; COMPLICATION; INTRADERMAL DRUG ADMINISTRATION; PRESCHOOL CHILD; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; FEMALE; FIJI; HUMANS; IMPETIGO; INSECTICIDES; IVERMECTIN; MALE; PERMETHRIN; PREVALENCE; SCABIES; SKIN CREAM; YOUNG ADULT;

EID: 84949454497     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1500987     Document Type: Article

References (45)

1. Scabies. Geneva: World Health Organization, 2015 (http://www.who.int/lymphatic-filariasis/epidemiology/scabies/en).
2. Jackson A, Heukelbach J, da Silva Filho AF, de Barros Campelo Júnior E, Feldmeier H. Clinical features and associated morbidity of scabies in a rural community in Alagoas, Brazil. Trop Med Int Health 2007; 12: 493-502.
3. Worth C, Heukelbach J, Fengler G, Walter B, Liesenfeld O, Feldmeier H. Impaired quality of life in adults and children with scabies from an impoverished community in Brazil. Int J Dermatol 2012; 51: 275-82.
4. Verma BL, Srivastava RN. Measurement of the personal cost of illness due to some major water-related diseases in an Indian rural population. Int J Epidemiol 1990; 19: 169-76.
5. Hay RJ, Estrada Castanon R, Alarcon Hernandez H, et al. Wastage of family income on skin disease in Mexico. BMJ 1994; 309: 848.
6. Taplin D, Porcelain SL, Meinking TL, et al. Community control of scabies: a model based on use of permethrin cream. Lancet 1991; 337: 1016-8.
7. Lawrence G, Leafasia J, Sheridan J, et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull World Health Organ 2005; 83: 34-42.
8. Wong LC, Amega B, Connors C, et al. Outcome of an interventional program for scabies in an indigenous community. Med J Aust 2001; 175: 367-70.
9. Heukelbach J, Wilcke T, Winter B, Feldmeier H. Epidemiology and morbidity of scabies and pediculosis capitis in resource-poor communities in Brazil. Br J Dermatol 2005; 153: 150-6.
10. Steer AC, Jenney AW, Kado J, et al. High burden of impetigo and scabies in a tropical country. PLoS Negl Trop Dis 2009; 3(6): e467.
11. Heukelbach J, Feldmeier H. Scabies. Lancet 2006; 367: 1767-74.
12. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-96.
13. Steer AC, Tikoduadua LV, Manalac EM, Colquhoun S, Carapetis JR, Maclennan C. Validation of an Integrated Management of Childhood Illness algorithm for managing common skin conditions in Fiji. Bull World Health Organ 2009; 87: 173-9.
14. Epidemiology and management of common skin diseases in children in developing countries. Geneva: World Health Organization, 2005 (http://www.who.int/maternal-child-adolescent/documents/fch-cah-05-12/en).
15. Thomas M, Woodfield G, Moses C, Amos G. Soil-transmitted helminth infection, skin infection, anaemia, and growth retardation in schoolchildren of Taveuni Island, Fiji. N Z Med J 2005; 118: U1492.
16. Romani L, Koroivueta J, Steer AC, et al. Scabies and impetigo prevalence and risk factors in Fiji: a national survey. PLoS Negl Trop Dis 2015; 9(3): e0003452.
17. La Vincente S, Kearns T, Connors C, Cameron S, Carapetis J, Andrews R. Community management of endemic scabies in remote aboriginal communities of northern Australia: low treatment uptake and high ongoing acquisition. PLoS Negl Trop Dis 2009; 3(5): e444.
18. Centers for Disease Control and Prevention. Global NTD programs. 2015 (http://www.cdc.gov/globalhealth/ntd/global-program.html).
19. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med 2010; 362: 717-25.
20. Mohammed KA, Deb RM, Stanton MC, Molyneux DH. Soil transmitted helminths and scabies in Zanzibar, Tanzania following mass drug administration for lymphatic filariasis - a rapid assessment methodology to assess impact. Parasit Vectors 2012; 5: 299.
21. Basáñez MG, Pion SD, Boakes E, Filipe JA, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and metaanalysis. Lancet Infect Dis 2008; 8: 310-22.
22. Twum-Danso NA, Meredith SE. Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis. Trop Med Int Health 2003; 8: 820-31.
23. Mackenzie CD, Geary TG, Gerlach JA. Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria J 2003; 2: Suppl 1: S5.
24. Task Force for Global Health. Atlanta: Mectizan Donation Program, 2015 (http://www.mectizan.org).
25. 2007 Census of population and housing - labour force, employment and unemployment. Suva: Fiji Bureau of Statistics, 2009 (http://www.statsfiji.gov.fj).
26. Walton SF, Currie BJ. Problems in diagnosing scabies, a global disease in human and animal populations. Clin Microbiol Rev 2007; 20: 268-79.
27. Onchocerciasis and its control: report of a WHO Expert Committee on Onchocerciasis Control. World Health Organ Tech Rep Ser 1995; 852: 1-104.
28. Central Australian Rural Practitioners Association. CARPA standard treatment manual. 5th ed. Alice Springs, NT, Australia: Centre for Remote Health, 2012.
29. Gardner MJ, Altman DG. Statistics with confidence. London: British Medical Journal, 1994: 51-2.
30. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219.
31. Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42: 236-40.
32. Engelman D, Martin DL, Hay RJ, et al. Opportunities to investigate the effects of ivermectin mass drug administration on scabies. Parasit Vectors 2013; 6: 106.
33. Mittal A, Garg A, Agarwal N, Gupta L, Khare AK. Treatment of nodular scabies with topical tacrolimus. Indian Dermatol Online J 2013; 4: 52-3.
34. Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev 2007; 3: CD000320.
35. Steer AC, Kearns T, Andrews RM, Mc-Carthy JS, Carapetis JR, Currie BJ. Ivermectin worthy of further investigation. Bull World Health Organ 2009; 87(10): A.
36. Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996; 55: 477-81.
37. Scientific Working Group on Serious Adverse Events in Loa Loa endemic areas: report of a Scientific Working Group on Serious Adverse Events following Mectizan treatment of onchocerciasis in Loa loa endemic areas. Filaria J 2004; 2: Suppl 1: S2.
38. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997; 350: 18-22.
39. Romani L, Steer AC, Whitfeld MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis 2015; 15: 960-7.
40. Leung V, Miller M. Detection of scabies: a systematic review of diagnostic methods. Can J Infect Dis Med Microbiol 2011; 22: 143-6.
41. Walter B, Heukelbach J, Fengler G, Worth C, Hengge U, Feldmeier H. Comparison of dermoscopy, skin scraping, and the adhesive tape test for the diagnosis of scabies in a resource-poor setting. Arch Dermatol 2011; 147: 468-73.
42. Chosidow O. Scabies. N Engl J Med 2006; 354: 1718-27.
43. Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis 2004; 39(1): e8-e12.
44. Currie B, Huffam S, O'Brien D, Walton S. Ivermectin for scabies. Lancet 1997; 350: 1551.
45. Engelman D, Kiang K, Chosidow O, et al. Toward the global control of human scabies: introducing the International Alliance for the Control of Scabies. PLoS Negl Trop Dis 2013; 7(8): e2167.